Vanguard disaggregates holdings; IDEXX (NASDAQ: IDXX) shows zero
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
IDEXX Laboratories Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately in reliance on SEC Release No. 34-39538.
Positive
- None.
Negative
- None.
FAQ
What does the Vanguard Schedule 13G/A for IDXX state?
It states that The Vanguard Group beneficially owns 0 shares and 0% of IDEXX common stock. The filing is an amendment explaining an internal realignment requiring certain subsidiaries to report holdings separately under SEC Release No. 34-39538.
Why did Vanguard file this amended Schedule 13G/A for IDEXX (IDXX)?
Vanguard explains an internal realignment effective January 12, 2026, that disaggregated reporting among subsidiaries. In reliance on SEC Release No. 34-39538, those subsidiaries now report beneficial ownership separately and The Vanguard Group no longer reports aggregated ownership for those holdings.
Who signed the Schedule 13G/A amendment for Vanguard regarding IDEXX?
The filing is signed by Ashley Grim, identified as Head of Global Fund Administration. The signature block shows the amendment date as 03/27/2026 and lists Vanguard's Malvern, Pennsylvania principal business address.